Customized Solutions

Microorganisms play a crucial role in pharmaceuticals, food production, and bioremediation. However, many companies and startups interested in industrial applications are still at the Minimum Viable Product (MVP) or Proof of Concept (POC) stage, requiring external expertise to translate concepts or laboratory results into commercial-scale applications.

Panlabs leverages its extensive expertise in microbial research and biotechnology to provide product-oriented development solutions that enable clients to achieve industrial-scale production. Our end-to-end development model—covering strain and enzyme optimization, genetic engineering, and scale-up manufacturing—delivers customized solutions with high success rates, shorter R&D cycles, and cost efficiency. We also welcome collaborative partnerships to jointly develop innovative products.

GLOBAL MICROBIAL STRAIN LIBRARY

Panlabs is a leading microbial development company with a comprehensive strain library of over 20,000 fungal and actinomycete strains sourced from diverse geographical and ecological environments worldwide. We provide high-value natural products and microbial-based solutions with broad applications in pharmaceuticals, agriculture, functional foods, cosmetics, and environmental sustainability. Our strain library is not subject to the Nagoya Protocol, allowing unrestricted access for the discovery of novel bioactive natural compounds. If you are interested in exploring our microbial strain resources, please feel free to contact us!

ENZYME IMPROVEMENT AND RECOMBINANT PROTEIN EXPRESSION SYSTEMS

Panlabs offers a comprehensive range of enzyme improvement and recombinant protein expression solutions, selecting the most suitable strategy based on client requirements:

High-Performance Enzyme and Protein Screening – Utilizing Panlabs' microbial strain library, we identify many enzymes or proteins from various microorganisms.
Enzyme and Protein Engineering – Applying genetic engineering techniques to enhance activity, stability, and thermal sensitivity to meet specific application needs.
Recombinant Protein Expression Platforms – Developing expression systems for E. coli, yeast, and other hosts, ensuring optimized yield and functionality.
Directed Evolution – Using enzyme evolution techniques to improve catalytic efficiency, selectivity, and versatility.
Cofactor and Additive Integration – Enhancing stability and performance by incorporating cofactors or auxiliary materials.
Examples – Includes amylase, lipase, glucose oxidase, and collagen.

Antibody-drug conjugate (ADC)

Antibody-drug conjugates (ADCs) are an advancement in drug development, delivering targeted cytotoxicity with enhanced clinical efficacy. An ADC consists of three key components: (1) Monoclonal antibody (mAb) – Targets cancer cells. (2) Small-molecule cytotoxic drug (Payload) – A potent cell-killing agent. (3) Linker – Attaches the payload to the antibody.

Common mechanisms of action of ADC drugs include tubulin inhibitors, DNA damaging agents, Topoisomerase 1 inhibitors, and Topoisomerase 2 inhibitors, all of which contribute to cancer cell death.

Panlabs specializes in the development and supply of various small-molecule cytotoxic drugs, including Ansamitocin P-3 (AP3), Mertansine (DM1), Calicheamicin, Belotecan, and Nemorubicin. Additionally, we offer both cleavable and non-cleavable linkers and welcome collaboration opportunities with interested companies for co-development.